Genome-Edited T Cell Therapies

Hematol Oncol Clin North Am. 2022 Aug;36(4):729-744. doi: 10.1016/j.hoc.2022.03.006. Epub 2022 Jun 27.


Chimeric antigen receptor (CAR) T-cells are widely being investigated against malignancies, and allogeneic 'universal donor' CAR-T cells offer the possibility of widened access to pre-manufactured, off-the-shelf therapies. Different genome-editing platforms have been used to address human leukocyte antigen (HLA) barriers to generate universal CAR-T cell therapy and early applications have been reported in children and adults against B cell malignancies. Recently developed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based systems and related technologies offer the prospect of enhanced cellular immunotherapies for a wider range of hematological malignancies.

Keywords: Base editor; CRISPR/Cas9; Chimeric antigen receptor; Cytidine deamination; Genome editing; T cell therapies.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems*
  • Child
  • Gene Editing / methods
  • Humans
  • Immunotherapy, Adoptive / methods
  • Neoplasms* / therapy
  • T-Lymphocytes